Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...

Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year that was below market expectations.The stock was down 0.2% Wednesday while ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

Abbott said that an ongoing multisite clinical study indicated that its rapid COVID-19 test was accurate when detecting the virus nearly 95% of the time. Abbott said that an ongoing multisite ...

Abbott Laboratories (ABT) reports robust sales growth and improved margins, setting the stage for continued success in 2025 ...

Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, ...

Abbott Laboratories and Decom will concentrate on competing in the huge market of potential continuous glucose monitor technology and put any patent disputes behind them for 10 years. North ...

BTIG analyst Marie Thibault maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 ...